Significance of nuclear hTra2-beta1 expression in cervical cancer

Acta Obstetricia et Gynecologica Scandinavica

Volumn 88, Issue 2, 2009, Pages 216-221

  Gabriel, Boris ^a   Hausen, Axel Zur ^a   Bouda, Jiri ^b   Boudova, Ludmila ^b   Koprivova, Miroslava ^b   Hirschfeld, Marc ^a   Jäger, Markus ^a   Stickeler, Elmar ^a,c  

^a UNIVERSITY OF FREIBURG   (Germany)

^b CHARLES UNIVERSITY   (Czech Republic)

^c NONE   (Germany)

Author keywords

Cervical cancer; hTra2 beta1; Splicing factor; Survival

Indexed keywords

ARTICLE; CARCINOGENESIS; CONTROLLED STUDY; CYTOPLASM; GENE; GENE EXPRESSION; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MORTALITY; PRIORITY JOURNAL; TRA2 BETA1 GENE; TUMOR LOCALIZATION; UTERINE CERVIX CANCER; ADENOCARCINOMA; ADULT; AGED; ALTERNATIVE RNA SPLICING; CELL NUCLEUS; CHEMISTRY; FEMALE; GENETICS; MIDDLE AGED; PATHOLOGY; SQUAMOUS CELL CARCINOMA; SURVIVAL; SURVIVAL RATE; UTERINE CERVIX TUMOR;

NERVE PROTEIN; NUCLEAR PROTEIN; RNA BINDING PROTEIN; SFRS10 PROTEIN, HUMAN;

ADENOCARCINOMA; ADULT; AGED; ALTERNATIVE SPLICING; CARCINOMA, SQUAMOUS CELL; CELL NUCLEUS; CYTOPLASM; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NERVE TISSUE PROTEINS; NUCLEAR PROTEINS; RNA-BINDING PROTEINS; SURVIVAL ANALYSIS; SURVIVAL RATE; UTERINE CERVICAL NEOPLASMS;

EID: 59649122661     PISSN: 00016349     EISSN: 16000412     Source Type: Journal    
DOI: 10.1080/00016340802503021     Document Type: Article

References (27)

1. Black DL. Protein diversity from alternative splicing: a challenge for bioinformatics and post.genome biology. Cell. 2000;103:367-70.
2. Blencowe BJ. Alternative splicing: new insights from global analyses. Cell. 2006;126:37-47.
3. Roberts GC, Smith CW. Alternative splicing: combinatorial output from the genome. Curr Opin Chem Biol. 2002;6:375-83.
4. Pajares MJ, Ezponda T, Catena R, Calvo A, Pio R, Montuenga LM. Alternative splicing: an emerging topic in molecular and clinical oncology. Lancet Oncol. 2007;8:349-57.
5. Skotheim RI, Nees M. Alternative splicing in cancer: noise, functional, or systematic. Int J Biochem Cell Biol. 2007;39:1432-49.
6. Venables JP. Aberrant and alternative splicing in cancer. Cancer Res. 2004;64:7647-54.
7. Faustino NA, Cooper TA. Pre-mRNA splicing and human disease. Genes Dev. 2003;17:419-37.
8. Fischer DC, Noack K, Runnebaum IB, Watermann DO, Kieback DG, Stamm S, et al. Expression of splicing factors in human ovarian cancer. Oncol Rep. 2004;11:1085-90.
9. Stoilov P, Meshorer E, Gencheva M, Glick D, Soreq H, Stamm S. Defects in pre-mRNA processing as causes of and predisposition to diseases. DNA Cell Biol. 2002;21:803-18.
10. Aigner A, Juhl H, Malerczyk C, Tkybusch A, Benz CC, Czubayko F. Expression of a truncated 100 kDa HER2 splice variant acts as an endogenous inhibitor of tumour cell proliferation. Oncogene. 2001;20:2101-11.
11. Ge K, Minhas F, Duhadaway J, Mao NC, Wilson D, Buccafusca R, et al. Loss of heterozygosity and tumor suppressor activity of Bin1 in prostate carcinoma. Int J Cancer. 2000;86:155-61.
12. Lukas J, Gao DQ, Keshmeshian M, Wen WH, Tsao-Wei D, Rosenberg S, et al. Alternative and aberrant messenger RNA splicing of the mdm2 oncogene in invasive breast cancer. Cancer Res. 2001;61:3212-9.
13. Stimpfl M, Tong D, Fasching B, Schuster E, Obermair A, Leodolter S, et al. Vascular endothelial growth factor splice variants and their prognostic value in breast and ovarian cancer. Clin Cancer Res. 2002;8:2253-9.
14. Wang L, Duke L, Zhang PS, Arlinghaus RB, Symmans WF, Sahin A, et al. Alternative splicing disrupts a nuclear localization signal in spleen tyrosine kinase that is required for invasion suppression in breast cancer. Cancer Res. 2003;63:4724-30.
15. Daoud R, Mies G, Smialowska A, Olah L, Hossmann KA, Stamm S. Ischemia induces a translocation of the splicing factor tra2-beta 1 and changes alternative splicing patterns in the brain. J Neurosci. 2002;22:5889-99.
16. Watermann DO, Tang Y, Zur Hausen A, Jager M, Stamm S, Stickeler E. Splicing factor Tra2-beta1 is specifically induced in breast cancer and regulates alternative splicing of the CD44 gene. Cancer Res. 2006;66:4774-80.
17. Erlandsson F, Martinsson-Ahlzen HS, Wallin KL, Hellstrom AC, Andersson S, Zetterberg A. Parallel cyclin E and cyclin A expression in neoplastic lesions of the uterine cervix. Br J Cancer. 2006;94:1045-50.
18. Delgado G, Bundy B, Zaino R, Sevin BU, Creasman WT, Major F. Prospective surgical-pathological study of diseasefree interval in patients with stage IB squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. Gynecol Oncol. 1990;38:352-7.
19. Daoud RDPBM, Siedler F, Hubener M, Stamm S. Activity-dependent regulation of alternative splicing patterns in the rat brain. Eur J Neurosci. 1999;11:788-802.
20. Schaal TD, Maniatis T. Multiple distinct splicing enhancers in the protein-coding sequences of a constitutively spliced pre-mRNA. Mol Cell Biol. 1999;19:261-73.
21. Hopkins MP, Morley GW. Stage IB squamous cell cancer of the cervix: clinicopathologic features related to survival. Am J Obstet Gynecol. 1991;164:1520-7.
22. Morice P, Piovesan P, Rey A, Atallah D, Haie-Meder C, Pautier P, et al. Prognostic value of lymphovascular space invasion determined with hematoxylin-eosin staining in early stage cervical carcinoma: results of a multivariate analysis. Ann Oncol. 2003;14:1511-7.
23. Boyle P, Ferlay J. Cancer incidence and mortality in Europe 2004. Ann Oncol. 2005;16:481-8.
24. Brenner H, Hakulinen T. Long-term cancer patient survival achieved by the end of the 20th century: most up-to-date estimates from the nationwide Finnish cancer registry. Br J Cancer. 2001;85:367-71.
25. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74-108.
26. Stickeler E, Fraser SD, Honig A, Chen AL, Berget SM, Cooper TA. The RNA binding protein YB-1 binds A/C-rich exon enhancers and stimulates splicing of the CD44 alternative exon v4. EMBO J. 2001;20:3821-30.
27. Mozzetti S, Ferrandina G, Marone M, D'Ingiullo F, Fruscella E, De Pasqua A, et al. Expression of bcl-2, bax-xL, and bcl-xS in endometrial and cervical tissues. Cancer Detect Prev. 2000;24:536-41.